New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 16, 2014
08:07 EDTTROVTrovagene announces clinical collaboratoin with Dana-Farber Cancer Institute
Trovagene announced that it has entered into a clinical collaboration with Dana-Farber Cancer Institute to investigate the utility of quantitative urine-based mutation detection and the ability to monitor tumor mutation burden and treatment response over time in metastatic melanoma patients. Under the agreement, urine samples will be collected from patients with locally advanced or metastatic melanoma known to harbor driver oncogene mutations.
News For TROV From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
October 8, 2015
16:09 EDTTROVTrovagene reports presentation of field experience analysis results with PCM
Trovagene announced the presentation of results from a field experience analysis featuring the use of its Precision Cancer Monitoring, or PCM, platform to accurately identify mutational status, which can be critical for physicians to determine appropriate therapy for patients. Mark Erlander, Ph.D. chief scientific officer of Trovagene is delivering the results today in an oral presentation titled CLIA Laboratory Testing of Urinary BRAF V600E DNA mutations: Application in the Management of Patients with Histiocytic Diseases at the 3rd Annual Erdheim-Chester International Medical Symposium, MD Anderson Cancer Center in Houston, Texas. The ability to quickly and accurately determine BRAF mutational status is very important to our patients with histiocytic disease when assessing therapeutic options," stated Filip Janku, M.D. Ph.D., of the University of Texas MD Anderson Cancer Center. "In patients that test positive for the mutation, the use of a BRAF inhibitor can offer a prolonged benefit that significantly improves their quality of life. We are encouraged by the recent advances in molecular diagnostic testing that can enable fast, accurate and non-invasive testing for our patients." Antonius Schuh, Ph.D., CEO of Trovagene, stated, "These data again demonstrate the ability of our urinary liquid biopsy platform to determine and monitor mutational status in patients when tissue biopsy is either inconclusive or unavailable. We are pleased to support the underserved histiocytic patient population for whom determining BRAF mutational status can be critical for therapeutic selection and improving treatment outcomes."

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the disclaimer & terms of use